

CITATION REPORT

List of articles citing

Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy

DOI: 10.1111/apt.12803

Alimentary Pharmacology and Therapeutics, 2014, 40, 123-32

Source: <https://exaly.com/paper-pdf/59213078/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
144	Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1074-80	6.1	79
143	Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. 2015 , 7, 926-41		61
142	The why and wherefore of hepatic encephalopathy. 2015 , 8, 381-90		8
141	Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. 2015 , 8, 159-67		13
140	Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11815-24	5.6	34
139	Rifaximin for people with hepatic encephalopathy. 2015 ,		3
138	Management Patterns of Hepatic Encephalopathy: A Nationwide Survey in India. <i>Journal of Clinical and Experimental Hepatology</i> , 2015 , 5, 199-203	4.1	2
137	PET and MR imaging of neuroinflammation in hepatic encephalopathy. 2015 , 30, 31-45		12
136	Presentation and complications associated with cirrhosis of the liver. 2015 , 31, 925-37		35
135	Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. 2015 , 13, 2048-61		105
134	Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. 2015 , 90, 1116-24		23
133	Recent advances in the treatment of hyperammonemia. 2015 , 90, 55-68		65
132	Primary Care Management of Hepatic Encephalopathy: A Common Cirrhosis Complication. 2015 , 11, 300-306		4
131	[Liver cirrhosis and the most common complications: diagnosis and treatment]. 2015 , 157 Suppl 1, 75-9		5
130	Palliative care for patients with end-stage liver disease. 2015 , 17, 440		24
129	Endomicroscopic and Transcriptomic Analysis of Impaired Barrier Function and Malabsorption in Environmental Enteropathy. 2016 , 10, e0004600		52
128	Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG. 2016 , 51, 1502-1506		7

127	Hepatic encephalopathy for the hospitalist. 2016 , 11, 591-4		
126	Gut Microbiota and the Liver: A Tale of 2 Cities: A Narrative View in 2 Acts. 2016 , 50 Suppl 2, Proceedings from t, S183-S187		5
125	Natural History of Patients Taking Rifaximin-For Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. 2016 , 38, 1081-1089.e4		12
124	Management of Hepatic Encephalopathy: A Primer. 2016 , 50, 569-77		11
123	Stepwise diagnosis in covert hepatic encephalopathy: critical flicker frequency and MELD-score as a first-step approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 514-21	6.1	16
122	Management of Neurologic Manifestations in Patients with Liver Disease. 2016 , 18, 37		7
121	Evidence-based clinical practice guidelines for liver cirrhosis 2015. 2016 , 51, 629-50		216
120	Role of rifaximin in the treatment of hepatic encephalopathy. 2016 , 39, 282-292		2
119	Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. 2016 , 10, 431-42		19
118	Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43 Suppl 1, 11-26	6.1	69
117	[Role of rifaximin in the treatment of hepatic encephalopathy]. 2016 , 39, 282-92		0
116	Hepatic Encephalopathy. 2017 , 47, 585-599		18
115	Neurosurgical Procedures in Patients with Cirrhosis and Acute Liver Failure: Indications, Safety, and Feasibility of Intracranial Pressure Monitor Devices. 2017 , 267-283		
114	Editorial: rifaximin in cirrhosis - is it what we've been waiting for?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1016-1017	6.1	0
113	Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. 2017 , 4, e000154		10
112	Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. 2017 , 29, 1109-1117		17
111	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. 2017 , 65, 592-603		47
110	Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. 2017 , 9, 12-19		21

109	The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention-A pilot study. 2017 , 12, e0185412		13
108	Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. 2017 , 5, 142-151		38
107	Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. 2018 , 9, 1373-1388		35
106	Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. 2018 , 36, 809-822		20
105	Update on the Therapeutic Management of Hepatic Encephalopathy. 2018 , 20, 21		12
104	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. 2018 , 67, 1568-1594		122
103	Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. 2018 , 33, 307-314		34
102	Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin. 2018 , 66, 1086-1091		16
101	Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. <i>Hepatology Research</i> , 2018 , 48, 411-423	5.1	22
100	Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta-analysis. 2018 ,		78
99	Mnemonic to Assist in Management of Liver Cirrhosis. 2018 , 14, 732-738		5
98	Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. 2019 , 13, 1-11		15
97	Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. 2018 , 11, 335-345		10
96	Intravenous and Oral Hyperammonemia Management. 2018 , 6, 182-193		
95	Astrocyte Pathophysiology in Liver Disease. 2018 ,		
94	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neopeptide collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. 2018 , 13, e0203200		4
93	Soporte paliativo en pacientes con enfermedad hepática avanzada: enfocar a necesidades más que a pronóstico. 2018 , 25, 237-245		
92	Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. 2018 , 19, 76-79		4

91	Acute care and emergency general surgery in patients with chronic liver disease: how can we optimize perioperative care? A review of the literature. 2018 , 13, 32		7
90	The Pharmabiotic Approach to Treat Hyperammonemia. 2018 , 10,		43
89	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. 2018 , 24, 355-366		11
88	Design of the GutHeart-targeting gut microbiota to treat heart failure-trial: a Phase II, randomized clinical trial. 2018 , 5, 977-984		25
87	Poly(ornithine)-based self-assembling drug for recovery of hyperammonemia and damage in acute liver injury. 2019 , 310, 74-81		13
86	Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy. <i>Hepatology Research</i> , 2019 , 49, 1406-1413	5.1	6
85	The efficacy and safety of rifaximin—a 2-year observational study of overt hepatic encephalopathy. 2019 , 12, 1756284819858256		4
84	Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. 2019 , 11, 489-512		19
83	Research Methods and Techniques for Acute Exacerbation of Chronic Hepatitis B. 2019 , 49-118		
82	Critically Ill Patients with End-Stage Liver Disease. 2019 , 37, 511-527		4
81	Effects of rifaximin versus nonabsorbable disaccharides in hepatic encephalopathy. 2019 , 1, 22-32		1
80	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1518-1527	6.1	22
79	[Hepatic cirrhosis: early diagnosis and prevention of complications]. 2019 , 161, 48-52		0
78	From germ theory to germ therapy. 2019 , 35, 73-82		5
77	The Gluten-Free Diet and Glycaemic Index in the Management of Coeliac Disease Associated with Type 1 Diabetes. 2019 , 35, 587-608		5
76	Treatment of Hepatic Encephalopathy. 2019 , 533-541		1
75	Brief Review of the Revised Korean Association for the Study of the Liver Clinical Practice Guidelines for Liver Cirrhosis: Varices, Hepatic Encephalopathy and Related Complications. 2019 , 74, 274		
74	Rethinking antimicrobial stewardship paradigms in the context of the gut microbiome. 2019 , 1, dlz015		6

73	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). 2019 , 51, 190-205		36
72	The Difficult Patient. 2020 , 287-308		
71	Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis. 2020 , 18, 800-812.e25		18
70	Current and emerging therapeutic options for the management of functional dyspepsia. 2020 , 21, 365-376		7
69	Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. 2020 , 85, 56-68		3
68	Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. <i>Journal of Hepatology</i> , 2020 , 73, 1526-1547	13.4	58
67	Letter: outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis-more questions than answers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 756	6.1	
66	Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1397-1405	6.1	19
65	Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. 2020 , 85, 56-68		1
64	Outcomes of lactulose plus branched-chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. <i>Hepatology Research</i> , 2020 , 50, 693-703	5.1	3
63	Hepatic Encephalopathy. 2020 , 615-629		4
62	Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis. <i>Internal Medicine</i> , 2020 , 59, 1849-1853 ^{1,1}		1
61	Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. 2021 , 15, 155-165		1
60	The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis. 2021 , 6, 8		2
59	Hepatische Enzephalopathie und Sarkopenie: pathogenetische Bedeutung und therapeutische Implikationen von Ammoniak. 2021 , 16, 160-171		
58	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. 2021 , 1, 4-52		31
57	Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. 2021 , 56, 560-569		6
56	Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy. 2021 , 8,		0

55	Role of serum albumin in hepatic encephalopathy. <i>Hepatology Research</i> , 2021 , 51, 353-354	5.1
54	Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy. 2021 , 5, 1518-1526	1
53	Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. 2021 , 167-174	
52	Diagnosis and Management of Hepatic Encephalopathy. 2021 , 25, 393-417	3
51	The Intestinal Microbiota Links Tea Polyphenols with the Regulation of Mood and Sleep to Improve Immunity. 1-14	2
50	Novel Agents in the Management of Hepatic Encephalopathy: A Review. 2021 , 9, 749-759	0
49	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <i>Hepatology Research</i> , 2021 , 51, 725-749	14
48	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. 2021 , 56, 593-619	27
47	Microbiome therapeutics for hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021 , 75, 1452-1464	13.4 7
46	Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. 2021 ,	0
45	Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial.. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 , 12, 336-342	4.1 1
44	Prognosis of patients with liver cirrhosis: A multi-center retrospective observational study. <i>Hepatology Research</i> , 2021 , 51, 1196-1206	5.1 0
43	Role of circadian rhythm and autonomic nervous system in liver function: a hypothetical basis for improving the management of hepatic encephalopathy. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 321, G400-G412	5.1 4
42	Microbiota Based Management of the Gastrointestinal Disorders. 2022 ,	
41	Neue Arzneimittel 2013. 2014 , 47-145	2
40	Magen-Darm-Mittel und Lebertherapeutika. 2017 , 539-561	2
39	Main Complications of AECHB and Severe Hepatitis B (Liver Failure). 2019 , 91-226	1
38	Neurologic Consequences of Liver Disease. 2018 , 203-219.e6	1

37	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 83-127	6.9	22
36	Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. <i>World Journal of Gastroenterology</i> , 2017 , 23, 8355-8366	5.6	52
35	Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. <i>World Journal of Gastroenterology</i> , 2019 , 25, 1817-1827	5.6	7
34	Role of gut microbiota via the gut-liver-brain axis in digestive diseases. <i>World Journal of Gastroenterology</i> , 2020 , 26, 6141-6162	5.6	17
33	Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. <i>Frontiers in Pharmacology</i> , 2021 , 12, 696065	5.6	0
32	Magen-Darm-Mittel und Lebertherapeutika. 2014 , 747-780		
31	Magen-Darm-Mittel und Lebertherapeutika. 2016 , 531-552		
30	Magen-Darm-Mittel und Lebertherapeutika. 2018 , 587-609		
29	Magen-Darm-Mittel und Lebertherapeutika. 2019 , 761-788		
28	Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy. <i>Acta Hepatologica Japonica</i> , 2020 , 61, 1-10	0.3	
27	Research Progress on the Relationship between Intestinal Flora and Mental and Psychological Diseases. <i>Advances in Microbiology</i> , 2020 , 10, 295-305	0.6	1
26	Magen-Darm-Mittel und Lebertherapeutika. 2020 , 615-642		
25	Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. <i>Internal Medicine</i> , 2020 , 59, 2465-2469	1.1	1
24	Complications of end-stage liver disease. <i>Canadian Family Physician</i> , 2016 , 62, 44-50	0.9	4
23	Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. <i>European Medical Journal (Chelmsford, England)</i> , 94-100	7.5	
22	Magen-Darm-Mittel und Lebertherapeutika. 2021 , 523-550		
21	Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 ,	4.1	0
20	Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	0

19	Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis.. <i>BMC Infectious Diseases</i> , 2022 , 22, 389	4	
18	<i>Clostridioides difficile</i> Infection in Liver Cirrhosis: A Concise Review. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022 , 2022, 1-12	2.8	1
17	EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. <i>Journal of Hepatology</i> , 2022 ,	13.4	4
16	Hepatic encephalopathy. <i>Nature Reviews Disease Primers</i> , 2022 , 8,	51.1	4
15	The Link between Gut Microbiota and Hepatic Encephalopathy. 2022 , 23, 8999		o
14	Hepatic Encephalopathy: Current and Emerging Treatment Modalities. 2022 , 20, S9-S19		o
13	The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study. 2022 , 85, 433-437		o
12	Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin- treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II). <i>flgastro-2022-102221</i>		o
11	Rifaximin stimulates nitrogen detoxification by PXR -independent mechanisms in human small intestinal organoids.		o
10	Pre- and Post-Portosystemic Shunt Placement Metabolomics Reveal Molecular Signatures for the Development of Hepatic Encephalopathy.		o
9	Diagnosis and Management of Hepatic Encephalopathy: The French Recommendations.		o
8	Cirrhosis management in the Intensive Care Unit.		o
7	Reduction in Gastrointestinal Cancers in Cirrhotic Patients Receiving Rifaximin vs Lactulose Only Therapy for Hepatic Encephalopathy. 2023 ,		o
6	Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy. 2023 , 118, 284-293		o
5	Magen/Darm- und Lebererkrankungen. 2022 , 303-328		o
4	Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis. 2023 , 7,		o
3	Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed.		o
2	Visi3 actual sobre el diagn3stico y los cuidados integrales en la encefalopat3 hep3tica. 2023 ,		o

- 1 Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Neurology, Peri-Transplant Medicine, Infectious Disease, and Gastroenterology Considerations. **2023**, 51, 657-676 ○